News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

No Impact With Mifepristone in Patients With Meningioma

Al's Comment:

 This is a small study, but the patients in the placebo group did better than those who took Mifepristone for meningiomas.



Website: http://www.cancertherapyadvisor.com/brain-cancer/meningioma-brain-cancer-mifepristone-no-treatment-benefit/article/451334/

Posted on: 11/04/2015

Stephen Cho
November 03, 2015
No Impact With Mifepristone in Patients With Meningioma
 
Share this article:
facebook
twitter
linkedin
google
Comments
Email
Print
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of failure-free or overall survival, according to a study published online ahead of print in the Journal of Clinical Oncology.1
 
In a multicenter, prospective, randomized, placebo-controlled phase 3 trial, researchers led by Yongli Ji, MD, of the University of Vermont Cancer Center in Burlington, VT, randomly assigned 164 patients to either mifepristone or placebo for 2 years or until disease progression.
 
Patients who were stable or had responded to therapy after 2 years had the option to continue therapy, and time to treatment failure and overall survival rate were measured.
 
 
RELATED: Proton Therapy Well-Tolerated for Low-Grade Gliomas
 
The researchers found that 24 patients were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. In addition, 28 patients in the placebo group were able to complete the 2-year study.
 
They observed no statistical difference between the 2 arms in terms of failure-free or overall survival, and concluded that long-term administration of mifepristone had no significant impact on this patient population.
 
Reference
 
Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 [published online ahead of print November 2, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.6490.

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740